fig4

Figure 4. CDEVs, PTX and CDEVs-PTX for tumor therapy in vivo. Their antitumor effects were assessed across four groups (n = 5). (A) Schematic representation of in vivo tumor therapy experiment in mice; (B and C) Body weight and survival rate in treated mice; (D and E) The size and weight of tumors in each group were assessed; (F) Tumor images were captured for each group; (G) Western blot data about the expression of PD-L1 in each group; (H) Flow cytometry data on PD-L1 expression were analyzed for each group; (I) Immunohistochemical tumor sections from the four groups were stained with Ki-67 and Cleaved-Caspase 3 markers. The sections show the positive staining regions for Ki-67 (upper panel) and Cleaved-Caspase 3 (lower panel). Scale bar: 100 μm. Data are represented as mean ± SD. CDEVs: Celery-derived extracellular vesicles; PTX: paclitaxel; CDEVs-PTX: CDEVs loaded with PTX; PBS: phosphate buffer solution. (n = 4; ^*P < 0.05; ^**P < 0.01; ^***P < 0.01; ^***P < 0.001).